The DOI matches its Crossref record; 295 of the 299 references it cites were found in a registry or an index.
Interpretation of the evidence for the efficacy and safety of statin therapy
Open accessAbstract
This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks and strokes. It explains how the evidence that is available from randomised controlled trials yields reliable information about both the efficacy and safety of statin therapy. In addition, it discusses how claims that statins commonly cause adverse effects reflect a failure to recognise the limitations of other sources of evidence about the effects of treatment. Large-scale evidence from randomised trials shows that statin therapy reduces the risk of major vascular events (ie, coronary deaths or myocardial infarctions, strokes, and coronary revascularisation procedures) by about one-quarter for each mmol/L reduction in LDL cholesterol during each year (after the first) that it continues to be taken. The absolute benefits of statin therapy depend on an individual's absolute risk of occlusive vascular events and the absolute reduction in LDL cholesterol that is achieved. For example, lowering LDL cholesterol by 2 mmol/L (77 mg/dL) with an effective low-cost statin regimen (eg, atorvastatin 40 mg daily, costing about £2 per month) for 5 years in 10 000 patients would typically prevent major vascular events from occurring in about 1000 patients (ie, 10% absolute benefit) with pre-existing occlusive vascular disease (secondary prevention) and in 500 patients (ie, 5% absolute benefit) who are at increased risk but have not yet had a vascular event (primary prevention). Statin therapy has been shown to reduce vascular disease risk during each year it continues to be taken, so larger absolute benefits would accrue with more prolonged therapy, and these benefits persist long term. The only serious adverse events that have been shown to be caused by long-term statin therapy-ie, adverse effects of the statin-are myopathy (defined as muscle pain or weakness combined with large increases in blood concentrations of creatine kinase), new-onset diabetes mellitus, and, probably, haemorrhagic stroke. Typically, treatment of 10 000 patients for 5 years with an effective regimen (eg, atorvastatin 40 mg daily) would cause about 5 cases of myopathy (one of which might progress, if the statin therapy is not stopped, to the more severe condition of rhabdomyolysis), 50-100 new cases of diabetes, and 5-10 haemorrhagic strokes. However, any adverse impact of these side-effects on major vascular events has already been taken into account in the estimates of the absolute benefits. Statin therapy may cause symptomatic adverse events (eg, muscle pain or weakness) in up to about 50-100 patients (ie, 0·5-1·0% absolute harm) per 10 000 treated for 5 years. However, placebo-controlled randomised trials have shown definitively that almost all of the symptomatic adverse events that are attributed to statin therapy in routine practice are not actually caused by it (ie, they represent misattribution). The large-scale evidence available from randomised trials also indicates that it is unlikely that large absolute excesses in other serious adverse events still await discovery. Consequently, any further findings that emerge about the effects of statin therapy would not be expected to alter materially the balance of benefits and harms. It is, therefore, of concern that exaggerated claims about side-effect rates with statin therapy may be responsible for its under-use among individuals at increased risk of cardiovascular events. For, whereas the rare cases of myopathy and any muscle-related symptoms that are attributed to statin therapy generally resolve rapidly when treatment is stopped, the heart attacks or strokes that may occur if statin therapy is stopped unnecessarily can be devastating.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although LDL-lowering drugs have only moderate effects on TG levels, they reduce ASCVD risk in patients with and without HTG.42”
From Clinical review on triglycerides (2020) · cites this paper as [42]
Experimental — accuracy not yet measuredIn the citing paper
“Although LDL-lowering drugs have only moderate effects on TG levels, they reduce ASCVD risk in patients with and without HTG.42”
From Clinical review on triglycerides (2020) · cites this paper as [42]
In the citing paper
“Overall, statin therapy produced a 21% relative reduction in major vascular events (relative risk 0.79, 95% CI 0.77-0.81) per 1.0 mmoL/L reduction in LDL-C”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [217]
In the citing paper
“However, since the absolute risk of CAD is higher in older persons, the associated absolute increase in risk for a given increment in TC is larger with increasing age [217].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [217]
In the citing paper
“The relative reduction in major vascular events was similar, irrespective of age, among patients with pre-existing vascular disease, but appeared smaller among older individuals not known to have vascular disease.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [217]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Reduced dietary salt for the prevention of cardiovascular disease
Taylor, R. S., Ashton, K. E., Moxham, T., Hooper, L., & Ebrahim, S. B. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009217.pub2 · Cited by 311
RetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Research works printed but not linked: 3
- Abramson, 2013, Don't Give More Patients Statins, The New York Times
- 2013, Statins can weaken muscles and joints: cholesterol drug raises risk of problems by up to 20 per cent, MailOnline
- 2016, How Big Pharma greed is killing tens of thousands around the world: Patients are over-medicated and often given profitable drugs with ‘little proven benefits,’ leading doctors warn, MailOnline
Cited by
Sorted by citations
Items 801–900 of 1,000
Statin-induced myopathy prevented by creatine administration
Balestrino, M., & Adriano, E. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-225395 · Cited by 10
Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease
Catapano, A. L., Tokgözoğlu, L. S., Silva, A. M. E., & Bruckert, É. (2019) · Atherosclerosis Supplements · doi:10.1016/j.athx.2019.100002 · Cited by 11
Management of familial hypercholesterolaemia in childhood
Ramaswami, U., & Humphries, S. E. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000943 · Cited by 10
Lipid-lowering Therapies in Myositis
Mizus, M. C., & Tiniakou, E. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00942-3 · Cited by 10
Zhou, E., Zhuang, L., Nakashima, H., Liu, C., Ying, Z., Foks, A. C., Berbée, J. F. P., van Dijk, K. W., Rensen, P. C. N., & Wang, Y. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.315882 · Cited by 10
Steinmeyer, J., & Flechtenmacher, J. (2021) · Zeitschrift für Orthopädie und Unfallchirurgie · doi:10.1055/a-1488-6912 · Cited by 10
Zeng, W., & Tomlinson, B. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-3660 · Cited by 10
Christensen, J. J., Bogsrud, M. P., Holven, K. B., Retterstøl, K., Veierød, M. B., & Nordeng, H. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.11.022 · Cited by 10
Bitto, N., Ghigliazza, G., Lavorato, S., Caputo, C., & Mura, V. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030934 · Cited by 11
Amarenco, P., Lavallée, P. C., Kim, J. S., Labreuche, J., Charles, H., Giroud, M., Lee, B., Mahagne, M., Meseguer, E., Nighoghossian, N., et al. (2023) · Stroke · doi:10.1161/strokeaha.123.042621 · Cited by 10
Katsanos, A. H., Lee, S. F., Cukierman‐Yaffe, T., Sherlock, L., Terrera, G. M., Canavan, M. D., Joundi, R. A., Sharma, M., Shoamanesh, A., Derix, A., et al. (2023) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2023.100176 · Cited by 11
Self-citationA systematic review and meta-analysis of the prevalence of dyslipidaemia among adults in Malaysia
Mohamed-Yassin, M.-S., Rosman, N., Kamaruddin, K. N., Miptah, H. N., Baharudin, N., Ramli, A. S., Abdul-Razak, S., Lai, N. M., & GLOBALDYS Study Investigators (2023) · Scientific Reports · doi:10.1038/s41598-023-38275-7 · Cited by 10
Anagnostis, P. G., Antza, C., Florentin, M., & Kotsis, V. (2023) · Kardiologia Polska · doi:10.33963/v.kp.97845 · Cited by 10
Inclisiran siRNA technology in the management of dyslipidemia: A narrative review of clinical trials
Olatunji, G. D., Kokori, E., Yusuf, I. A., Akinmoju, O. D., Egbunu, E. O., Muogbo, I., Lema, K. F., Kanagala, S. G., Owolabi, S., Muili, A. O., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102419 · Cited by 10
Kim, M., Cho, Y. K., Jung, C. H., & Lee, W. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111125 · Cited by 9
Chen, C., Wei, F., Dong, Y., & Liu, C. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07587-9 · Cited by 10
Proietti, M., Laroche, C., Nyvad, O., Haberka, M., Vassilikos, V. P., Maggioni, A. P., Boriani, G., & Lip, G. Y. H. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.08.055 · Cited by 10
Chen, P.-H., Wang, J., Lin, S.-Y., Li, C.-H., Wang, C.-Y., Hu, C.-Y., Fu, C., Tsai, Y.-T., Lee, A.-T., Chen, Y., et al. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1439829 · Cited by 10
Unmet Patient Need in Statin Intolerance: the Clinical Characteristics and Management
Harrison, T. N., Hsu, J.-W. Y., Rosenson, R. S., Levitan, E. B., Muntner, P., Cheetham, T. C., Wei, R., Scott, R. D., & Reynolds, K. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6775-0 · Cited by 10
Acquired low cholesterol: diagnosis and relevance to safety of low LDL therapeutic targets
Soran, H., Ho, J. H., & Durrington, P. N. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000526 · Cited by 10
Yeh, J., Syue, S.-H., Lin, C., Hsu, C. Y., Shae, Z., & Kao, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.05.002 · Cited by 10
Upstroke Time Per Cardiac Cycle is Associated with Cardiovascular Prognosis in Type 2 Diabetes
Chang, L.-H., Hwu, C., Chu, C., Won, J. G. S., Chen, H.-S., & Lin, L. (2019) · Endocrine Practice · doi:10.4158/ep-2019-0078 · Cited by 8
Hammad, M. A., Abdo, M. S., Mashaly, A. M., Sulaiman, S. A. S., Alghamdi, S., Mangi, A. A., & Noor, D. A. M. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.07.005 · Cited by 10
Timimi, F. K., Ray, S., Jones, E., Aase, L. A., & Hoffman, K. D. (2019) · Journal of Medical Internet Research · doi:10.2196/14809 · Cited by 10
Hjell, G., Mørch-Johnsen, L. E., Holst, R., Tesli, N., Bell, C., Lunding, S. H., Rødevand, L. N., Werner, M. C. F., Melle, I. S., Andreassen, O. A., et al. (2020) · Brain and Behavior · doi:10.1002/brb3.1751 · Cited by 10
Update on Preventive Cardiology
Clauss, S. B., & de Ferranti, S. D. (2020) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2020.06.006 · Cited by 10
Ferrannini, E., & Rosenstock, J. (2021) · Diabetes Care · doi:10.2337/dc20-0913 · Cited by 10
Role of Drug–Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity
Jessurun, N. T., Drent, M., Wijnen, P. A. H. M., Harmsze, A. M., van Puijenbroek, E., Bekers, O., & Bast, A. (2021) · Drug Safety · doi:10.1007/s40264-021-01105-8 · Cited by 11
Palacio-Portilla, E. J., Roquer, J., Amaro, S., Arenillas, J. F., Martín, Ó. A., Castellanos, M., Freijo, M. M., Fuentes, B., Pastor, Á. G., Gomis, M., et al. (2022) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.07.021 · Cited by 10
Aspirin for Primary Stroke Prevention; Evidence for a Differential Effect in Men and Women
Gdovinová, Z., Kremer, C., Lorenzano, S., Dawson, J., Lal, A., & Caso, V. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.856239 · Cited by 13
Lauritzen, T., Munkhaugen, J., Peersen, K., Kristiansen, O., Sverre, E., Nebauer, S., Villseth, M., Andersen, A., Svarstad, A. C., Jensen, E. P., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2844 · Cited by 10
Does addressing prediabetes help to improve population health?
Mika Kivimaki, B., & Tabák, Á. G. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30030-5 · Cited by 10
Genser, B., Wanner, C., & März, W. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320905721 · Cited by 10
Safety and efficacy of statins
Thompson, P. D., & Taylor, B. A. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30718-3 · Cited by 10
Prescribing Statins to Reduce Cardiovascular Disease: 10 Common Misconceptions
Schade, D. S., Shey, L., & Eaton, R. P. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.042 · Cited by 10
Genetic drug target validation using Mendelian randomizationPreprint
Schmidt, A. F., Finan, C., Gordillo‐Marañón, M., Asselbergs, F. W., Freitag, D. F., Patel, R. S., Tyl, B., Chopade, S., Faraway, R., Zwierzyna, M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/781039 · Cited by 10
Statins and Cognitive Impairment
Iadecola, C., & Parikh, N. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.09.040 · Cited by 10
Women’s Cardiovascular Health After Hypertensive Pregnancy
Honigberg, M. C., & Natarajan, P. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.01.064 · Cited by 10
Enhancing the Operational Semantics of the Entity-Relationship Model.
Parent, C. E., & Spaccapietra, S. (1985) · Discovery Science · Cited by 10
Mazhar, F., Hjemdahl, P., Sjölander, A., Kahan, T., Jernberg, T., & Carrero, J. J. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.12.010 · Cited by 10
Effectiveness of Coenzyme Q10 Supplementation in Statin-Induced Myopathy: A Systematic Review
Ahmad, K., Manongi, N. J., Rajapandian, R., Wala, S. M., AlEdani, E. M., Samuel, E. A., & Franchini, A. P. A. (2024) · Cureus · doi:10.7759/cureus.68316 · Cited by 11
Cheng, Z., Gao, M., Liu, Y., Yan, W., Zhang, Z., Jiao, N., & Li, C. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.10.017 · Cited by 11
Laufs, U., Lincoff, A. M., Nicholls, S. J., Li, N., Bloedon, L. T., Sasiela, W. J., Powell, H. A., Herout, P. M., Thompson, P. D., & Nissen, S. E. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.014 · Cited by 10
Steinfeldt, J., Wild, B., Buergel, T., Pietzner, M., zu Belzen, J. U., Vauvelle, A., Hegselmann, S., Denaxas, S., Hemingway, H., Langenberg, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55879-x · Cited by 11
Fusco, S. A. D., Volpe, M., Nardi, F., Matteucci, A., Aquilani, S., Marino, G., Aiello, A., & Colivicchi, F. (2025) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-025-00708-x · Cited by 9
Shah, P. K., Glueck, C. J., Goldenberg, N., Min, S., Mahida, C., Schlam, I. M., Rothschild, M., Huda, A. N., & Wang, P. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0416-7 · Cited by 9
Safety of Ospemifene during Real-Life Use
Bruyniks, N. (2018) · Journal of Gynecology and Womens Health · doi:10.19080/jgwh.2018.09.555762 · Cited by 9
Current Medical and Surgical Stroke Prevention Therapies for Patients with Carotid Artery Stenosis
Jusufovic, M., Skagen, K. R., Krohg‐Sørensen, K., & Skjelland, M. (2019) · Current Neurovascular Research · doi:10.2174/1567202616666190131162811 · Cited by 9
Zhao, S., Tian, Y., Yan, H., Zhang, B., Li, J., Xing, L., & Liu, L. (2019) · Medical Science Monitor · doi:10.12659/msm.917798 · Cited by 9
Statin drugs might boost healthy gut microbes
Libby, P. (2020) · Nature · doi:10.1038/d41586-020-01281-0 · Cited by 9
Tomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
Sarraju, A., Spencer‐Bonilla, G., Chung, S., Gomez, S. E., Li, J., Heidenreich, P. A., Palaniappan, L. P., & Rodríguez, F. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07107-7 · Cited by 9
Kim, J., Kang, D., Park, H., Kang, M., Choi, K. H., Park, T. K., Lee, J. M., Yang, J. H., Song, Y. B., Choi, J., et al. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07256-1 · Cited by 9
Geldsetzer, P., Neve, J. D., Mohan, V., Prabhakaran, D., Roy, A., Tandon, N., Davies, J. I., Vollmer, S., Bärnighausen, T., & Prenissl, J. (2022) · Global Heart · doi:10.5334/gh.1056 · Cited by 10
Kytö, V., Saraste, A., & Tornio, A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.06.1019 · Cited by 10
Statins in depression: a repurposed medical treatment can provide novel insights in mental health
Giorgi, R. D., Cowen, P. J., & Harmer, C. J. (2022) · International Review of Psychiatry · doi:10.1080/09540261.2022.2113369 · Cited by 10
Tomida, J., Yoshida, T., Senda, S., Sato, T., Nakatsuma, A., & Iihara, N. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5622 · Cited by 12
Pacheco, R., & Coelho, M. (2023) · Life · doi:10.3390/life13061325 · Cited by 9
Angelopoulos, N., Paparodis, R. D., Androulakis, I. P., Boniakos, A., Argyrakopoulou, G., & Livadas, S. (2023) · Nutrients · doi:10.3390/nu15122682 · Cited by 9
Karalis, D. G. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000896 · Cited by 9
PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis
Bodapati, A. P., Hanif, A., Okafor, D. K., Katyal, G., Kaur, G., Ashraf, H., & Khan, S. (2023) · Cureus · doi:10.7759/cureus.46605 · Cited by 15
Cho, J., Park, I. B., Lee, K., Ahn, T. H., Park, W. B., Kim, J. H., Ahn, Y., Jeong, M. H., & Lee, D. H. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.10.009 · Cited by 9
Ingrand, I., Solinas, M., Ingrand, P., Dugast, E., Saulnier, P., Pérault‐Pochat, M., & Lafay‐Chebassier, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-21819-7 · Cited by 9
How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner
Cardoso, R. N., Blumenthal, R. S., Kopecky, S. L., López-Jiménez, F. A., & Martin, S. S. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.011 · Cited by 10
Self-citationNever too old for statin treatment?
Cheung, B. M. Y., & Lam, K. S. L. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32263-3 · Cited by 9
Management of high cholesterol levels in older people
Bertolotti, M., Lancellotti, G., & Mussi, C. (2019) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.13647 · Cited by 11
Evaluation of statins impacts on cognitive function among diabetic patients
Hammad, M. A., Sulaiman, S. A. S., Aziz, N. A., & Noor, D. A. M. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.04.006 · Cited by 9
The effect of HMG-CoA reductase inhibitors on thrombolysis-induced haemorrhagic transformation
Wu, Y., Lu, D., & Xu, A. (2019) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2019.08.074 · Cited by 9
Yousufuddin, M., Zhu, Y., Al-Ward, R., Peters, J., Doyle, T., Jensen, K. L., Wang, Z., & Murad, M. H. (2020) · Open Heart · doi:10.1136/openhrt-2019-001163 · Cited by 9
Cai, B., Lin, P., Wang, Z.-B., Zhang, M., & Peng, B. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.104793 · Cited by 9
Leontyeva, I. V. (2020) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2020-65-4-27-40 · Cited by 9
Robinson, J. G., Jayanna, M. B., Merz, C. N. B., & Stone, N. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240166 · Cited by 9
Pavlović, J., Greenland, P., Franco, O. H., Kavousi, M., Ikram, M. K., Deckers, J. W., Ikram, M. A., & Leening, M. J. G. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007183 · Cited by 9
Brunette, C. A., Dong, O. M., Vassy, J. L., Danowski, M. E., Alexander, N. V. J., Antwi, A. A., & Christensen, K. D. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111123 · Cited by 9
Smith, M. C., Ashdown, H. F., Sheppard, J. P., Butler, C., & Bankhead, C. R. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-050757 · Cited by 9
Gu, S. Z., Costopoulos, C., Huang, Y., Bourantas, C. V., Woolf, A. K., Sun, C. J., Teng, Z., Losdat, S., Räber, L., Samady, H., et al. (2021) · European Heart Journal Open · doi:10.1093/ehjopen/oeab039 · Cited by 10
Heinrich, N. S., Pedersen, R. P., Vestergaard, M. B., Lindberg, U., Andersen, U. B., Haddock, B., Hansen, T. W., Fornoni, A., Larsson, H. B. W., & Rossing, P. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15146 · Cited by 9
Yamada, K., Brousseau, M. E., Honma, W., Iimura, A., Imase, H., Iwaki, Y., Kawanami, T., LaSala, D., Liang, G., Mitani, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00900 · Cited by 9
Smith, I. B., Schmidt, R., Halm, E. A., & Mansi, I. A. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0589-x · Cited by 9
Im, E., Cho, Y., Suh, Y., Cho, D., Her, A., Kim, Y. H., Lee, K., Kang, W. C., Yun, K. H., Yoo, S., et al. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2017.05.028 · Cited by 9
Emerging Trends in Clinical Research With Implications for Population Health and Health Policy
Chin-Yee, B. H., Subramanian, S. V., Verma, A. A., Laupacis, A., & Razak, F. A. (2018) · Milbank Quarterly · doi:10.1111/1468-0009.12328 · Cited by 11
Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort
Probstfield, J. L., Boden, W. E., Anderson, T. J., Branch, K. R., Kashyap, M. L., Fleg, J. L., Desvigne-Nickens, P. M., McBride, R., & McGovern, M. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.07.007 · Cited by 9
Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
Parhofer, K. G., Chapman, M. J., & Nordestgaard, B. G. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa116 · Cited by 11
Statin treatment and increased diabetes risk. Possible mechanisms
Climent, E., Benaiges, D., & Pedro‐Botet, J. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.10.003 · Cited by 9
Nissen, S. E. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.019 · Cited by 9
Who Benefits From Taking a Statin, and When?
Leening, M. J. G. (2020) · Circulation · doi:10.1161/circulationaha.120.048340 · Cited by 9
Blokhina, A. V., Ershova, A. I., Kiseleva, A. V., Sotnikova, E. A., Zharikova, A. A., Zaicenoka, M., Vyatkin, Y. V., Ramensky, V. E., Kutsenko, V. A., Garbuzova, E. V., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312651 · Cited by 8
Cárdenas, J. D. G., Oliveira, V. H. F., Borsari, A. L., Marinello, P. C., Longenecker, C. T., & Deminice, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-31643-3 · Cited by 8
Mohajer, B., Moradi, K., Guermazi, A., Dolatshahi, M., Roemer, F. W., Ibad, H. A., Parastooei, G., Conaghan, P. G., Zikria, B. A., Wan, M., et al. (2023) · Skeletal Radiology · doi:10.1007/s00256-023-04473-7 · Cited by 8
Comparative Effectiveness of Rosuvastatin Versus Atorvastatin in Acute Ischemic Stroke Treatment
Kim, J., Lee, J. S., Kim, H., Kim, B. J., Kang, J., Lee, K., Park, J., Kang, K., Lee, S. J., Kim, J. G., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038080 · Cited by 8
Interventions that inform patients about nocebo effects: A systematic review of the current evidence
Spotts, E. K., & Geers, A. L. (2025) · Annals of Behavioral Medicine · doi:10.1093/abm/kaaf067 · Cited by 8
A practical guide to the management of dyslipidaemia
Siegel, P. M., Katzmann, J. L., Weinmann‐Menke, J., Landmesser, U., Schunkert, H., Baldus, S. E., Böhm, M., Laufs, U., Lüscher, T. F., & Hilgendorf, I. (2026) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02833-y · Cited by 10
Cesena, F. Y., Valente, V. A., Santos, R. D., & Bittencourt, M. S. (2020) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20190519 · Cited by 8
Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists
Patel, D. K., & Busch, R. S. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211023715 · Cited by 9
Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides
Pareek, M., Mason, R. P., & Bhatt, D. L. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1954158 · Cited by 8
Volpe, M., & Patrono, C. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab647 · Cited by 8
Kwon, O., Na, W., Hur, J., Kim, J. H., Jun, T. J., Kang, H. J., Lee, H., & Kim, Y. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07255-2 · Cited by 8
Aggressive lipid-lowering therapy after percutaneous coronary intervention – for whom and how?
Lee, Z.-V., & Lam, H. (2022) · AsiaIntervention · doi:10.4244/aij-d-22-00005 · Cited by 8
Mortensen, M. B., Sand, N. P. R., Busk, M., Jensen, J. M., Grove, E. L., Dey, D., Iraqi, N., Updegrove, A. R., Fonte, T. A., Mathiassen, O. N., et al. (2022) · Clinical Cardiology · doi:10.1002/clc.23895 · Cited by 8
Statin Therapy and the Risk of Viral Infection: A Retrospective Population-Based Cohort Study
Wu, B., Chen, D.-H., Liao, W.-C., Ho, W., Yin, M., Lin, C., Chou, C.-H., & Peng, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195626 · Cited by 8
Metadata
- Authors
- Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., Evans, S., Law, M., MacMahon, S., Martin, S., Neal, B., Poulter, N., Preiss, D., Ridker, P., Roberts, I., Rodgers, A., Sandercock, P., Schulz, K., Sever, P., Simes, J., Smeeth, L., Wald, N., Yusuf, S., & Peto, R.
- Affiliations
- University of Oxford (GB)
- Johns Hopkins University (US)
- University of Cambridge (GB)
- University of Bristol (GB)
- University of Wisconsin–Madison (US)
- University of London (GB)
- The University of Sydney (AU)
- Imperial College London (GB)
- Brigham and Women's Hospital (US)
- University of Edinburgh (GB)
- University of North Carolina at Chapel Hill (US)
- Population Health Research Institute (CA)
- Corresponding author
- Collins, Rory
- ORCID
- Collins, Rory
- Reith, Christina
- Emberson, Jonathan
- Armitage, Jane
- Baigent, Colin
- Blumenthal, Roger
- Danesh, John
- Smith, George Davey
- DeMets, David
- Evans, Stephen
- MacMahon, Stephen
- Martin, Seth
- Neal, Bruce
- Poulter, Neil
- Preiss, David
- Ridker, Paul
- Roberts, Ian
- Rodgers, Anthony
- Sandercock, Peter
- Schulz, Kenneth
- Smeeth, Liam
- Wald, Nicholas
- Yusuf, Salim
- Peto, Richard
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 388
- Issue
- 10059
- Pages
- 2532-2561
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2519634482
- Cited by
- 1,857
- References
- 299
- Citations by year
- 2026: 136 · 2025: 136 · 2024: 150 · 2023: 166 · 2022: 187 · 2021: 229 · 2020: 192 · 2019: 218 · 2018: 206 · 2017: 202 · 2016: 31
- FWCI
- 43.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion, other-oa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by-nc-nd)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Funders
- Cancer Research UK (16896)
- National Institute for Health and Care Research (NF-SI-0611-10057, HTA/14/49/159, 14/49/159, NF-SI-0513-10059)
- British Heart Foundation (SP/08/010/25939, SP/14/3/31114, RG/13/13/30194)
- Medical Research Council (MR/K006584/1, MR/L003120/1)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- statin therapy, LDL cholesterol lowering, cardiovascular disease prevention, secondary prevention, primary prevention, absolute risk reduction, statin adverse effects, myopathy, rhabdomyolysis, new-onset diabetes, hemorrhagic stroke, atorvastatin, long-term treatment, evidence evaluation, cardiovascular risk assessment, cost-effectiveness, randomized controlled trials, meta-analysis
- MeSH terms
- Anticholesteremic Agents, Clinical Trials as Topic, Coronary Disease, Humans, Cholesterol, LDL, Myocardial Infarction, Safety, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Stroke, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
